Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators with Rheumatoid Arthritis

Arthritis Care and Research

Volumn 67, Issue 12, 2015, Pages 1656-1663

  Bonafede, MacHaon ^a   Johnson, Barbara H ^a   Tang, Derek H ^b   Shah, Neel ^b   Harrison, David J ^b   Collier, David H ^b  

^a IBM WATSON HEALTH   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FACTUAL DATABASE; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LOGISTIC MODELS; MALE; MEDICARE PART B; MEDICATION ADHERENCE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84956646955     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22638     Document Type: Article

References (33)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
3. Enbrel (etanercept) prescribing information. Thousand Oaks (CA): Immunex Corporation; 2013.
4. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al., A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
5. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al., Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. Arthritis Rheum 2003; 48: 1493-9.
6. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al., Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369: 307-18.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
8. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al., A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64: 2824-35.
9. Van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W., Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009; 36: 2164-70.
10. De Achaval S, Suarez-Almazor ME., Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol 2010; 5: 313-26.
11. Blum MA, Koo D, Doshi JA., Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: A systematic review. Clin Ther 2011; 33: 901-13.
12. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG., Low rates of adherence for tumor necrosis factor-alpha inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review. World J Gastroenterol 2013; 19: 4344-50.
13. Harrold LR, Andrade SE., Medication adherence of patients with selected rheumatic conditions: A systematic review of the literature. Semin Arthritis Rheum 2009; 38: 396-402.
14. Agarwal S, Zaman T, Handa R., Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 2009; 50: 686-92.
15. Salt E, Frazier SK., Predictors of medication adherence in patients with rheumatoid arthritis. Drug Dev Res 2011; 72: 756-63.
16. Lyles A, Culver N, Ivester J, Potter T., Effects of health literacy and polypharmacy on medication adherence. Consult Pharm 2013; 28: 793-9.
17. Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al., Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: Consequences of low adherence. Arthritis Rheum 2013; 65: 1421-9.
18. Contreras-Yanez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V., Persistence on therapy is a major determinant of patient-, physician- and laboratory-reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol 2010; 28: 748-51.
19. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V., Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010; 340: 282-90.
20. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al., Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009; 15: 457-64.
21. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J., The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697-704.
22. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al., Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998; 279: 1458-62.
23. Gurwitz JH, Yeomans SM, Glynn RJ, Lewis BE, Levin R, Avorn J., Patient noncompliance in the managed care setting: The case of medical therapy for glaucoma. Med Care 1998; 36: 357-69.
24. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al., The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166: 332-7.
25. Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, et al., Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther 2011; 13: R155.
26. Salt E, Frazier SK., Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A narrative review of the literature. Orthop Nurs 2010; 29: 260-75.
27. Van den Bemt BJ, Zwikker HE, van den Ende CH., Medication adherence in patients with rheumatoid arthritis: A critical appraisal of the existing literature. Expert Rev Clin Immunol 2012; 8: 337-51.
28. Muller R, Kallikorm R, Polluste K, Lember M., Compliance with treatment of rheumatoid arthritis. Rheumatol Int 2012; 32: 3131-5.
29. Hill J, Bird H, Johnson S., Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. Ann Rheum Dis 2001; 60: 869-75.
30. Brus HL, van de Laar MA, Taal E, Rasker JJ, Wiegman O., Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis 1998; 57: 146-51.
31. Zwikker HE, van den Ende CH, van Lankveld WG, den Broeder AA, van den Hoogen FH, van de Mosselaar B, et al., Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. Patient Educ Couns 2014; 94: 356-61.
32. Homer D, Nightingale P, Jobanputra P., Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Musculoskeletal Care 2009; 7: 78-92.
33. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML., Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health 2009; 12: 1053-61.